UCB announced that its Head of Neurology Solutions Charl van Zyl has decided to leave the company to become CEO of Lundbeck, a global pharmaceutical company specialized in brain diseases. His successor at UCB and the timing of his departure will be announced in due course. Charl van Zyl joined UCB in 2017 to head the company's operations before transitioning to head its neurology business globally.

He is currently also responsible for corporate activities both in Europe and International markets. During his tenure, Charl has overseen the growth of the epilepsy business while building up the company's new rare disease assets and integrating activities from both Ra Pharma and Zogenix.